Treatment Trials

4 Clinical Trials for Various Conditions

Focus your search

RECRUITING
Natural History Study for Charcot Marie Tooth Disease
Description

The goal of this Natural History Study for Charcot-Marie-Tooth is to acquire, record, and analyze patient-reported data and associated genetic reports, Electronic Health Records (EHRs) and clinical notes to identify the burden, diagnostic journey, and prevalence of disease that will aid scientists in their work toward finding a cure. Participants will be asked to complete a Natural History Survey.

Conditions
Charcot-Marie-Tooth DiseaseCharcot-Marie-ToothCharcot-Marie-Tooth Disease, Type IACharcot-Marie-Tooth Disease Type 2ACharcot-Marie-Tooth Disease Type 2Charcot-Marie-Tooth Disease, Type 2CCharcot-Marie-Tooth Disease Type 2A2BCharcot-Marie-Tooth Disease Type 2B2Charcot-Marie-Tooth Disease Type 2A1Charcot-Marie-Tooth Disease Type 4B1Charcot-Marie-Tooth Disease, Type IBCharcot-Marie-Tooth Disease Type 2B1Charcot-Marie-Tooth Disease Type 2U (Diagnosis)Charcot-Marie-Tooth Disease Type 4ACharcot-Marie-Tooth Disease, Type 4A, Axonal FormCharcot-Marie-Tooth Disease Type 2A2ACharcot-Marie-Tooth Disease Type 2S (Disorder)Charcot-Marie-Tooth Disease and DeafnessCharcot-Marie-Tooth Disease Type 4B2Charcot-Marie-Tooth Disease Type 4HCharcot-Marie-Tooth Disease Type 1FCharcot-Marie-Tooth Disease Type 4CCharcot-Marie-Tooth Disease Type 4ECharcot-Marie-Tooth Disease Type 1DCharcot-Marie-Tooth Disease Type 2Q (Diagnosis)Charcot-Marie-Tooth Disease Type 2A2Charcot-Marie-Tooth Disease Type 2N (Diagnosis)Charcot-Marie-Tooth Disease Type 2B5Charcot-Marie-Tooth Disease Type 2DCharcot-Marie-Tooth Disease Type 4DCharcot-Marie-Tooth Disease Type 2KCharcot-Marie-Tooth Disease Type 2L (Diagnosis)Charcot-Marie-Tooth Disease Type 2TCharcot-Marie-Tooth Disease Type 2ICharcot-Marie-Tooth Disease Type 2JCharcot-Marie-Tooth Disease Type 2ECharcot-Marie-Tooth Disease Type 2GCharcot-Marie-Tooth Disease Type 1CCharcot-Marie-Tooth Disease Type 2RCharcot-Marie-Tooth Disease Type 2O (Diagnosis)Charcot-Marie-Tooth Disease Type 2MCharcot-Marie-Tooth Disease Type 2PCharcot-Marie-Tooth Disease Type 2YCharcot-Marie-Tooth Disease Type 4F (Diagnosis)Charcot-Marie-Tooth Disease Type 4B3Charcot-Marie-Tooth Disease Type 2HHNPPX-Linked Charcot-Marie-Tooth Disease
RECRUITING
Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease
Description

This Phase 2a study aims to evaluate the efficacy, safety and tolerability of NMD670 vs placebo administered twice a day (BID) for 21 days in ambulatory adult patients with Charcot-Marie-Tooth disease type 1 and type.

COMPLETED
Observational Study of Neuromuscular Function in CMT Type 1&2 and Healthy Controls
Description

The primary aim of this study is to discover whether patients with CMT type 1 and 2 have neuromuscular junction transmission deficits. The secondary aim is to collect information of different clinical and electrophysiological test procedures to perform possible future clinical trials in CMT patients.

RECRUITING
A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders
Description

Background: Pyrimidine and purine metabolism disorders (DPPMs) affect how the body metabolizes chemicals called pyrimidines and purines. DPPMs can cause dysfunctions throughout the body, especially in the brain, blood, kidneys, and immune system. People with DPPMs might have no symptoms, mild symptoms, or they may have severe, chronic symptoms, that can be fatal. DPPMs are not well understood, and researchers want to learn more about what causes them and how to treat them. Objective: To learn more about factors that affect DPPMs by comparing test results from affected, uaffected family members, and healthy people. Eligibility: Three types of participants are needed: people aged 1 month and older with DPPMs; their family members who do not have DPPMs; and healthy volunteers. Design: Participants with DPPMs will come to the clinic once a year; some may be asked to come more often. At each visit, all affected participants will have a physical exam and give samples of blood, urine, saliva, and stool. Depending on their symptoms, they may also have other procedures, such as: Swabs of their skin and inside the mouth. Tests of their heart, kidney, brain, and nerve function. Questionnaires about what they eat. Dental exams, and exams of their hearing and vision. Tests of their learning ability. Monitoring of their physical activity. Imaging scans. Photographs of their face and body. These tests may be spread over up to 7 days. Affected participants may remain in the study indefinitely if they wish to. Healthy volunteers and family members will have 1 study visit. They will have a physical exam and may be asked to give blood, urine, saliva, and stool samples.

Conditions
AMPD3, OMIM*102772, AMP Deaminase DeficiencyAK1, OMIM *103000, Adenylate Kinase DeficiencyAMPD1, OMIM *102770, Myopathy Due to Myoadenylate Deaminase DeficiencyTPMT, OMIM *187680, Thoipurines, Poor Metabolism ofIMPDH1, OMIM *146690, Retinitis Pigmentosa Type 10, Leber Congenital Amauriosis Type 11APRT, OMIM *102600, Adenine Phosphoribosyltransferase DeficiencyHPRT1, OMIM *308000 Lesch-Nyhan DiseaseXDH, OMIM *607633, Xanthinuria Type 1SLC2A9, OMIM *606142 HypouricemiaSLC22A12, OMIM *607096 HypouricemiaPRPS1 Def, OMIM *311850, Arts Syndrome; Charcot-Marie-Tooth DiseasePRPS1 SA, OMIM *311850 Gout, PRPS-related Phosphoribosylpyrophosphate Synthetase SuperactivityAMPD2, OMIM *102771, Spastic Paraplegia 63; Pontocerebellar HypoplasiaITPA, OMIM *147520, Inosine Triphosphatase Deficiency; Developmental and Epileptic Encephalopathy 35ADSL, OMIM *608222, Adenylosuccinate Lyase DeficiencyPNP, OMIM *164050, Nucleoside Phosphorylase DeficiencyADA2, OMIM *607575,Sneddon Syndrome; VAIHSCAD, *1140120, Developmental and Epileptic EncephalopathyUPB1, OMIM *606673, Beta-ureidopropionase DeficiencyDPYS, OMIM *613326, Dihydropyrimidinase DeficiencyDPYD, OMIM *274270, Dihydropyrimidine Dehydrogenase DeficiencyDHODH, OMIM *126064, Miller Syndrome (Postaxial Acrofacial Dysostosis)UMPS, OMIM *613891, Orotic AciduriaNT5C3A<TAB>, OMIM *606224, Anemia, Hemolytic, Due to UMPH1 DeficiencyUNG, OMIM *191525, Hyper-IgM Syndrome 5AICDA, OMIM *605257, Immunodeficiency With Hyper-IgM, Type 2; HIGM2Purine-Pyrimidine MetabolismMetabolic Disease